Free Trial
NASDAQ:LIPO

Lipella Pharmaceuticals Q4 2024 Earnings Report

Lipella Pharmaceuticals logo
$2.46 0.00 (0.00%)
As of 10:19 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Lipella Pharmaceuticals EPS Results

Actual EPS
-$1.19
Consensus EPS
-$2.43
Beat/Miss
Beat by +$1.24
One Year Ago EPS
N/A

Lipella Pharmaceuticals Revenue Results

Actual Revenue
$0.17 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Lipella Pharmaceuticals Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, March 27, 2025
Conference Call Time
7:00PM ET

Upcoming Earnings

Lipella Pharmaceuticals' Q1 2025 earnings is scheduled for Thursday, May 8, 2025

Earnings Documents

Lipella Pharmaceuticals Earnings Headlines

Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.
See More Lipella Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lipella Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lipella Pharmaceuticals and other key companies, straight to your email.

About Lipella Pharmaceuticals

Lipella Pharmaceuticals (NASDAQ:LIPO), a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

View Lipella Pharmaceuticals Profile

More Earnings Resources from MarketBeat